[³H]-BIBP3226 and [³H]-NPY Binding to Intact SK-N-MC Cells and CHO Cells Expressing the Human Y₁ Receptor

References

• Grundemar L., Skeikh S. P., Wahlestedt C. Characterization of Receptor Types for Neuropeptide Y and Related Peptides. The Biology of Neuropeptide Y and Related Peptides, W.F. Colmers, C. Wahlestedt. Humana Press, Inc., Totowa, N.J. 1993; 197–239
   Google Scholar
• Playford R. J., Cox H. M. Peptide YY and neuropeptide Y: two peptides intimately involved in electrolyte homeostasis. Trends Pharmacol. Sci. 1996; 17: 436–438
   PubMed Web of Science ®Google Scholar
• Michel M. C., Beck-Sickinger A., Cox H., Doods H. N., Herzog H., Larhammer D., Quirion R., Schwartz T., Westfall T. XVI. International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY and Pancreatic Polypeptide Receptors. Pharmacol. Rev. 1998; 50: 143–150
   PubMed Web of Science ®Google Scholar
• Inui A., Sano K., Miura M., Hirosue Y., Nakajima M., Okita M., Baba S., Kasuga M. Evidence for further heterogeneity of the receptors for Neuropeptide-Y and Peptide-YY in tumor cell lines derived from neural crest. Endocrinology 1992; 131: 2090–2096
   PubMedGoogle Scholar
• Skeikh S. P., HÅKanson R., Schwartz T. W. Y1and Y2receptors for neuropeptide Y. FEBS Letts. 1989; 245: 209–214
   PubMedGoogle Scholar
• Wahlestedt C., Regunathan S., Reis D. J. Identification of cultured cells selectively expressing Y1-, Y2-, or Y3-type receptors for neuropeptide Y/peptide YY. Life. Sci. 1991; 50: PL-7–12
   Google Scholar
• Michel M. C., Gaida W., Beck-Sickinger G., Wieland H. A., Doods H., DÜRr H., Schnorrenberg G. Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic activity. Mol. Pharmacol. 1992; 42: 642–648
   Google Scholar
• Wieland H. A., Willim K., Doods H. N. Reeptor binding profiles of NPY analogues and fragments in different tissues and cell lines. Peptides 1995; 16: 1389–1394
   PubMed Web of Science ®Google Scholar
• Rudolf K., Eberlein W., Engel W., Wieland H. A., Willim K. D., Entzeroth M., Wienen W., Beck-Sickinger A. G., Doods H. N. The first highly potent and selective non-peptide neuropeptide Y1receptor antagonist BIBP3226. Eur. J. Pharmacol. 1994; 271: R11–R13
   PubMed Web of Science ®Google Scholar
• Serradeil-Le Gal C., Valette G., Rouby P. E., Pellet A., Villanova G., Foulon L., Neliat G., Chambon J. P., Maffrand J. P., Le Fur G. SR120107A and SR120819A: Two potent and selective, orally effective antagonists for NPY Y1receptors. Am. Soc. Neurosci. Abstr. 1994; 20: 907–R13
   Google Scholar
• Serradeil-Legal C., Valette G., Rouby P. E., Pellet A., Oury-Donat F., Brossard G., Lespy L., Marty E., Neliat G., De Cointet P., Maffrand J. P., Le Fur G. SR120819A, an orally-active and selective neuropeptide Y Y1receptor antagonist. FEBS Letts. 1995; 362: 192–196
   Google Scholar
• Hedge S. S., Bonhaus D. W., Stanley W., Eglen R. M., Moy T. M., Loeb M., Shetty S. G., Desouza A., Kristenansky J. Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y-Y1receptor antagonist. J. Pharamacol. Exp. Ther. 1995; 275: 1261–1266
   Google Scholar
• Michel M. C., Feth F., Steineker M., Rascher W. NPY and carbachol raise Ca2+in SK-N-MC cells by three different mechanisms. Naun. Schmiedebergs. Arch. Pharmacol. 1992; 345: 370–374
   Google Scholar
• Gordon E. A., Kohout T. A., Fishman P. H. Characterization of functional neuropeptide Y receptors in a human neuroblastoma cell line. J. Neurochem. 1990; 55: 506–513
   PubMed Web of Science ®Google Scholar
• Skeikh S. P., O'Hare M. M.T., Tortora O., Schwartz T. W. Binding of monoiodinated neurpeptide Y to hippocampal membranes and human neuroblastoma cell lines. J. Bioch. Chem. 1989; 264: 6648–6654
   Google Scholar
• Herzog H., Hort Y. J., Ball H. J., Hayes G., Shine J., Selbie L. A. Cloned human neuropeptide Y couples to two different second messenger systems. Proc. Natl. Acad. Sci. USA 1992; 89: 5794–5798
   PubMed Web of Science ®Google Scholar
• Lobaugh L. A., Blackshear P. J. Neuropeptide Y binding and inhibition of cAMP accumulation in human neuroepithelioma cells. Am. J. Physiol. 1990; 258: C913–C922
   Google Scholar
• Aakerlund L., Gether U., Fuhlendorf J., Schwartz T. W., Thastrup O. Y1receptors for neuropeptide Y are coupled to mobilization of intracellular calcium and inhibition of adenylate cyclase. FEBS Letts. 1989; 260: 73–78
   Google Scholar
• Daniels A. J., Matthews J. E., Viveros O. H., Lazarowski E. R. Characterization of the neuropeptide Y-induced intracellular calcium release in human erythroleukemic cells. Mol. Pharmacol. 1992; 41: 767–771
   Google Scholar
• Van Liefde I., Vanderheyden P. M.L., Fraeyman N., Debacker J. P., Vauquelin G. Human neuropeptide Y Y1 receptors exert unequal control of the extracellular acidification rate in different cell lines. Eur. J. Pharmacol., in press
   Google Scholar
• Vanderheyden P. M.L., Van Liefde I., Debacker J. P., Vauquelin G. Effect of BIBP3226 on inositol phosphate accumulation and cytosolic calcium level in control and NPY Y1 receptor expressing CHO-K1 cells. Reg. Peptides, in press.
   Google Scholar
• Entzeroth M., Braunger H., Eberlein W., Engel W., Rudolf K., Wienen W., Wieland H. A., Willim K. D., Doods H. N. Labeling of neuropeptide Y receptors in SK-N-MC cells using the novel, nonpeptide Y1receptor-selective antagonist [3H]-BIBP3226. Eur. J. Pharmacol. 1995; 278: 239–242
   Google Scholar
• Wieland H. A., Willim K. D., Entzeroth M., Wienen W., Rudolf K., Eberlein W., Engel W., Doods H. N. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP3226. J. Pharmacol. Exp. Ther. 1995; 275: 143–149
   PubMedGoogle Scholar
• Vanderheyden P. M.L., Van Liefde I., Debacker J. P., Vauquelin G. Non-competitive binding of the nonpeptide antagonist BIBP3226 to rat forebrain neuropeptide Y1receptors. Eur. J. Pharmacol. 1997; 331: 275–284
   Google Scholar
• Severne Y., Ijzerman A., Nerme V., Zimmerman H., Vauquelin G. Shallow agonist competition binding curves for β-adrenergic receptors: The role for tight agonist binding. Mol. Pharmacol. 1986; 31: 69–73
   Google Scholar
• Convents A., Debacker J. P., Vauquelin G. Tight agonist binding may prevent the correct interpretation of agonist competition binding curves ofα2-adrenergic receptors. Mol. Pharmacol. 1987; 32: 65–115
   Google Scholar
• Feth F., Rascher W., Michel M. C. G-Protein coupling and signalling of Y1-like neuropeptide Y receptors in SK-N-MC cells. Naun. Schmiedebergs. Arch. Pharmacol. 1991; 344: 1–7
   Google Scholar
• Shigeri Y., Fujimoto M. Two different signal transductions of neuropeptide Y1 receptor in SK-N-MC cells. Biochem. Biophys. Res. Commun. 1992; 187: 1565–1571
   PubMed Web of Science ®Google Scholar
• Schwartz T. W. Locating ligand binding sites in 7TM receptors by protein engineering. Curr. Opin. Biotechnol. 1994; 5: 434–444
   PubMedGoogle Scholar
• Gether U., Johansen T. E., Schwartz T. W. Different binding epitopes on the NK1 receptor for substance P and non-peptide antagonists. Nature 1993; 362: 345–348
   PubMed Web of Science ®Google Scholar